---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-345733"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2026-08-12T11:15:23+00:00"
generated_at: "2026-08-12T11:20:14.009874+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sutro Q2 revenue drops to $9.8M from $63.7M; STRO-004 shows early responses

## Summary
- Revenue $9.8M vs $63.7M in Q2 2025; cash $164.3M vs $202.6M at March 31, 2026.
- STRO-004 Phase 1: confirmed and unconfirmed partial responses in pancreatic, head/neck, NSCLC at 3-4 mg/kg; discontinuation rate 6%.
- STRO-004 PK: half-life ~7 days, DAR8 preserved, 25-50% more ADC exposure with 50% less payload vs conventional.
- STRO-006 Phase 1 start expected Q3 2026; STRO-227 IND on track for 2026.
- Astellas collaboration: $10M milestone received April 2026; second iADC program to enter clinic by end 2026.

## SEC filing metadata
- accession: 0001193125-26-345733
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2026-08-12T11:15:23+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000119312526345733/0001193125-26-345733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000119312526345733/stro-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-345733
- JSON: https://secwatch.observer/filing/0001193125-26-345733.json
- Plain text: https://secwatch.observer/filing/0001193125-26-345733.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.